Financial Performance - The company expects a net profit attributable to shareholders for the first half of 2024 to be between -500,000 and -4,500,000 RMB, indicating a loss [4]. - The previous year's earnings per share was 0.0018 RMB [6]. - The company reported a significant loss from changes in fair value of financial assets, amounting to approximately -21 million RMB, which is a deterioration from -1.24 million RMB in the same period last year [12]. - The estimated net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between 7.5 million and 11 million RMB [15]. - The total profit for the current period is estimated at 4.01 million RMB, with a net profit attributable to shareholders of 998,600 RMB [18]. Earnings Forecast - The company has indicated that there are no major uncertainties that could affect the accuracy of the earnings forecast [20].

北京市盈科（南宁）律师事务所 法律意见书 北京市盈科（南宁）律师事务所 关于柳州两面针股份有限公司 2023 年年度 股东大会的法律意见书 盈科（桂）法意字（2024）第 L-01 号 致：柳州两面针股份有限公司 北京市盈科（南宁）律师事务所接受柳州两面针股份有限公司（以 下简称"公司"）的委托，指派本所律师对公司召开 2023 年年度股东大 会（以下简称"本次股东大会"或"会议"）的有关事项进行见证并出 具法律意见。 为出具法律意见，本所律师审查了公司提供的有关会议文件、资料， 并出席了本次股东大会进行现场见证。公司保证其已向本所律师提供了 出具法律意见所必须的、真实的、完整的书面材料。 基于对上述文件、资料的审查和现场见证情况，本所律师根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》、《上市公司股东大会规则》（以下简称"《股东大会规则》"）、 《上海证券交易所上市公司股东大会网络投票实施细则》、《柳州两面 针股份有限公司章程》（以下简称"《公司章程》"）、《股东大会议 事规则》等有关规定，按照律师行业公认的业务标准、道德规范和勤勉 尽责的精神，对本次股东大会发表法律意见 ...

证券代码：600249 证券简称：两面针 公告编号：2024-011 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (五) 公司董事、监事和董事会秘书的出席情况 柳州两面针股份有限公司 2023 年年度股东大会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 10 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 216,477,299 | | 3、出席会议的股东所持有表决权股份数占公司有 | | | 表决权股份总数的比例（%） | 39.3595 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主 持情况等。 会议由公司董事会召集，董事长林钻煌先生主持，采取现场投票 及网络投票相结合的方式召开并表决。会议的召集和召开符合《公司 法》和《公司章程》的规定，做出的决议合法、有效。 (一) 股东大会召开的时间：2024 年 6 月 27 日 (二) 股东大会召开的地点：广西柳州市东环大道 282 号两面针办 ...

柳州两面针股份有限公司（以下简称"公司"）第八届董事会、监 事会任期将于近期届满，鉴于公司第九届董事会候选人、监事会候选 人的提名工作尚未完成，预计在原定任期届满前无法完成换届工作。 为确保公司董事会、监事会相关工作的连续性和稳定性，公司第八届 董事会、监事会将延期换届，董事会各专门委员会及高级管理人员的 任期亦相应顺延。 在公司董事会、监事会换届选举完成之前，公司第八届董事会成 员、监事会成员、董事会各专门委员会成员及高级管理人员将严格按 照相关法律法规和《柳州两面针股份有限公司章程》的规定继续履行 董事、监事、董事会专门委员会委员及高级管理人员的义务和职责。 证券代码：600249 证券简称：两面针 公告编号：临2024-010 柳州两面针股份有限公司 关于董事会、监事会延期换届 及独立董事任期届满的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会、监事会延期换届 二、独立董事任期届满 根据《中华人民共和国公司法》《上市公司独立董事管理办法》 等相关规定，独立董事在上市公司连续任职时间不得超过六 ...

柳州两面针股份有限公司 2023 年年度股东大会 目录 | 2023 | 年年度股东大会会议须知 | 1 | | --- | --- | --- | | 2023 | 年年度股东大会会议安排 | 2 | | 议案一： 2023 | 年度董事会工作报告 | 3 | | 议案二： | 年度监事会工作报告 2023 | 9 | | 议案三： | 2023 年度财务决算报告 | 12 | | 议案四： | 年年度报告（全文及摘要） 2023 | 15 | | 议案五： | 2023 年度利润分配预案 | 16 | | 议案六： | 关于授权管理层贷款的议案 | 17 | | 议案七： | 关于修订公司《独立董事工作制度》的议案 18 | | | 听取：2023 | 年度独立董事述职报告 | 33 | 2 柳州两面针股份有限公司 2023 年年度股东大会会议须知 各位股东： 为了维护股东的合法权益，确保公司股东大会的会议秩序和议事 效率，保证大会顺利进行，公司根据《公司法》《证券法》《上市公 司股东大会规则》《公司章程》及《股东大会议事规则》等规定，特 制定本须知。 会议资料 股票简称：两面针 股票代码：600249 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 207,794,818.22, representing a year-on-year increase of 10.55%[5] - The net profit attributable to shareholders was a loss of CNY 1,274,521.77, with a significant decline compared to a profit of CNY 4,587,640.30 in the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,225,506.29, an increase from CNY 608,600.76 in the previous year[9] - The basic earnings per share for the quarter were -CNY 0.0023, a decrease from CNY 0.0083 in the same period last year[9] - Net profit for Q1 2024 was a loss of CNY 1.17 million, compared to a net profit of CNY 4.67 million in Q1 2023, representing a decline of 125.06%[21] - The company's basic earnings per share for Q1 2024 was -CNY 0.0023, down from CNY 0.0083 in Q1 2023[22] - The company reported a total profit loss of CNY 4.42 million in Q1 2024, compared to a profit of CNY 6.68 million in Q1 2023[21] Cash Flow - The net cash flow from operating activities was a negative CNY 14,258,810.76, indicating cash outflow during the quarter[5] - Cash inflow from operating activities in Q1 2024 was CNY 276.58 million, compared to CNY 210.05 million in Q1 2023, reflecting an increase of 31.6%[22] - Cash outflow from operating activities in Q1 2024 totaled CNY 290.84 million, up from CNY 227.76 million in Q1 2023, indicating a rise of 27.7%[23] - The net cash flow from operating activities for Q1 2024 was -CNY 14.26 million, an improvement from -CNY 17.71 million in Q1 2023[23] - Investment activities resulted in a net cash outflow of CNY 8.20 million in Q1 2024, compared to CNY 4.53 million in Q1 2023[23] - Total cash inflow from financing activities was $25 million, compared to $35 million in the previous period, indicating a decrease of 28.57%[24] - Cash outflow for debt repayment increased significantly to $34 million from $13 million, representing a rise of 161.54%[24] - The net cash flow from financing activities was negative at -$9.42 million, contrasting with a positive cash flow of $21.7 million in the prior period[24] - The net increase in cash and cash equivalents was -$31.88 million, compared to a slight decrease of -$531,420.43 previously[24] - The ending balance of cash and cash equivalents stood at $1.25 billion, down from $1.27 billion at the beginning of the period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,622,389,607.62, showing a slight increase of 0.02% from the previous year[6] - The company's total current assets as of March 31, 2024, amounted to RMB 1,887,460,942.80, slightly up from RMB 1,883,579,504.99 at the end of 2023[14] - Cash and cash equivalents decreased to RMB 1,245,946,790.26 from RMB 1,277,823,841.14, reflecting a decline of approximately 2.5%[14] - Inventory increased significantly to RMB 296,013,647.83, up from RMB 252,292,080.98, marking a rise of about 17.3%[14] - Total liabilities as of March 31, 2024, were RMB 507,357,843.94, compared to RMB 505,751,467.09 at the end of 2023, indicating a slight increase[16] - The company's total assets reached RMB 2,622,389,607.62, a marginal increase from RMB 2,621,957,721.33 at the end of 2023[16] - The total equity attributable to shareholders was RMB 2,118,575,810.45, slightly down from RMB 2,119,850,332.22[16] - The equity attributable to shareholders was CNY 2,118,575,810.45, down 0.06% from the end of the previous year[6] Government Support and Expenses - The company received government subsidies amounting to CNY 2,740,383.68, which positively impacted the financial results[7] - Total operating costs for Q1 2024 were CNY 203.36 million, an increase of 8.16% from CNY 188.02 million in Q1 2023[20] - The company’s financial expenses in Q1 2024 were -CNY 11.06 million, compared to -CNY 5.85 million in Q1 2023, indicating a significant increase in financial costs[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,647[10] Product Development and Strategy - The company has not disclosed any significant new product developments or market expansion strategies during this reporting period[13] Accounting Standards - The company did not apply new accounting standards or interpretations starting in 2024[24]

证券代码：600249 证券简称：两面针 公告编号：临2024-008 柳州两面针股份有限公司 2024 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 柳州两面针股份有限公司（以下简称"公司"）根据上海证券交 易所《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第 十三号——化工》的要求，现将 2024 年第一季度主要经营数据披露如 下： 一、 主要产品的产量、销量及收入实现情况 | 主要产品 | 2024 年 月 | 1-3 | | 2024 年 1-3 月 | | 2024 年 月 | 1-3 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 产量（万支） | | | 销量（万支） | | 营业收入（万元） | | | | 家用牙膏 | | | 870.85 | | 746.21 | | | 3,277.45 | | 旅游牙膏 | | | 30,324.48 | | 30,710.94 | | | ...

证券代码：600249 证券简称：两面针 公告编号：临 2024-007 柳州两面针股份有限公司 关于召开 2023 年度业绩说明会的公告 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 4 月 9 日（星期二）至 4 月 15 日（星期 一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 lmzstock@lmz.com.cn 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 柳州两面针股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日披露公司 2023 年年度报告，为便于广大投资者更全面深入地 了解公司 2023 年度经营成果、财务状况，公司计划于 2024 年 4 月 16 日下午 15:00-16:00 举行 2023 年度业绩说明会，就投资者关心的问 题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 本公司董事会 ...

Financial Performance - In 2023, the company achieved a net profit attributable to shareholders of RMB 22,806,658.88, a significant recovery from a net loss of RMB 38,589,058.32 in 2022, marking an increase of 159.1% year-on-year[5]. - The total operating revenue for 2023 was RMB 995,136,283.16, representing a year-on-year increase of 48.71% compared to RMB 669,192,032.18 in 2022[25]. - The net cash flow from operating activities for 2023 was RMB 38,368,320.17, an increase of 39.12% compared to RMB 27,580,148.16 in 2022[25]. - The company reported a net asset value attributable to shareholders of RMB 2,119,850,332.22, reflecting a slight increase of 1.09% from RMB 2,097,043,673.34 at the end of 2022[26]. - The basic and diluted earnings per share for 2023 were 0.0415 yuan, a significant improvement from -0.0702 yuan in 2022[27]. - The company achieved a revenue of 995 million yuan in 2023, representing a year-on-year growth of 48.71%[27]. - The company reported a significant increase in comprehensive gross profit due to improved sales performance[27]. - The cash flow from operating activities showed a positive trend, with a notable increase in the second and fourth quarters[29]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of RMB 0.3 per 10 shares, totaling RMB 16,500,000, based on a total share capital of 550,000,000 shares[5]. - The cash dividend amount represents 72.35% of the net profit attributable to ordinary shareholders in the consolidated financial statements[155]. - The company maintains a cash dividend policy that requires a minimum of 10% of the distributable profit to be allocated for cash dividends each year[152]. - The company plans to distribute dividends based on a total share capital of 550,000,000 shares, with a proposed cash dividend distribution of at least 10% of the distributable profit for the year[152]. Operational Highlights - The company completed 19 new product development and upgrade projects in the oral care category, launching five new product series[37]. - Online and offline sales increased, with revenue from the personal care segment reaching 179 million yuan, a year-on-year increase of 25.07%[37]. - The company actively expanded its market presence by enhancing product research and development and optimizing operations on platforms like Tmall and Douyin[37]. - The company is focused on brand building and innovation to strengthen its core competitiveness in the herbal daily chemical sector[37]. - The company launched 24 new domestic oral care products under the brand "Two-Needles" and developed 13 new oral care products under the EMO brand during the reporting period[80]. Risk Management and Compliance - The company has outlined potential risks in its future development, including industry and market risks, which investors should consider[7]. - The company has no non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[6]. - There are no violations of decision-making procedures regarding external guarantees, indicating compliance with regulations[6]. - The company has established a comprehensive corporate governance structure, ensuring clear responsibilities among its power, decision-making, supervisory, and management bodies[116]. Environmental and Social Responsibility - The company has invested a total of 567,700 CNY in poverty alleviation and rural revitalization projects, benefiting 137 individuals[177]. - The company has installed photovoltaic power generation equipment, generating approximately 900,000 kWh of electricity annually, promoting the use of clean energy[174]. - The company has adopted measures to reduce carbon emissions, including using clean energy and developing environmentally friendly products[173]. - The company actively participates in social responsibility initiatives and will disclose its 2023 social responsibility report on March 29, 2024[175]. Governance and Management - The company has established a performance evaluation system to enhance its incentive framework, emphasizing value creation and skill improvement[146]. - The company has a diverse board with members holding various positions in other companies, indicating a broad network and experience[130]. - The company is led by a team with significant experience in finance, engineering, and management, enhancing its operational capabilities[131]. - The company has maintained a stable leadership structure with no changes in shareholding among key executives during the reporting period[128]. Financial Position and Assets - As of the end of 2023, the total assets of the company were RMB 2,476,174,283.0, a decrease of 1.94% from RMB 2,525,233,959.3 at the end of 2022[26]. - The total value of fixed assets decreased to 88.189 billion RMB from 91.798 billion RMB, reflecting a decline of approximately 4.5%[68]. - The total value of intangible assets decreased to 21.741 billion RMB from 22.355 billion RMB, reflecting a decline of approximately 2.7%[68]. - The company's long-term equity investment balance was approximately 160.89 million RMB, including investments in five subsidiaries[92]. Research and Development - The company's R&D expenses amounted to 15,705,583.61, representing 1.58% of total revenue[57]. - The number of R&D personnel is 157, making up 10.16% of the total workforce[58]. - The company added 5 invention patents and 3 design patents during the reporting period, contributing to its competitive advantage[80]. Market Competition and Strategy - The company faces intensified market competition in the daily chemical industry, with increasing pressure on pricing, R&D technology, and service quality[113]. - The company is actively improving its channel layout to adapt to the rapidly changing retail landscape in China, ensuring alignment with consumer purchasing habits[114]. - The strategic focus is on integrating traditional Chinese medicine with daily chemical products to improve consumer quality of life[111].

柳州两面针股份有限公司 关于 2023 年度会计师事务所履职情况的评估报告 柳州两面针股份有限公司（以下简称"公司"）聘请中喜会计师 事务所（特殊普通合伙）作为公司 2023 年度审计机构。根据《中华 人民共和国公司法》《国有企业、上市公司选聘会计师事务所管理办 法》等相关规定，公司对会计师事务所 2023 年度审计履职情况进行 了评估，具体情况如下： 一、会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 名称：中喜会计师事务所（特殊普通合伙） 成立日期：2013 年 11 月 注册地址：北京市东城区崇文门外大街 11 号 11 层 1101 室 组织形式：特殊普通合伙企业 首席合伙人：张增刚先生 中喜会计师事务所（特殊普通合伙）（以下简称"中喜"或"该所"） 最早于 1985 年成立，1993 年，经财政部和中国证券监督管理委员会 批准，授予该所 执行证券期货相关业务许可证；2013 年 11 月 8 日 经北京市财政局批准，改制设立为中喜会计师事务所（特殊普通合伙)。 元，其中：审计业务收入 27,348.82 万元；证券业务收入 10,321.94 万 元。2022 年度服务上市公司客户 ...